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Fungal biofilm infections have become increasingly recognised as a significant clinical problem. One of the major reasons behind
this is the impact that these have upon treatment, as antifungal therapy often fails and surgical intervention is required. This places
a large financial burden on health care providers. This paper aims to illustrate the importance of fungal biofilms, particularly
Candida albicans, and discusses some of the key fungal biofilm resistance mechanisms that include, extracellular matrix (ECM),
eﬄux pump activity, persisters, cell density, overexpression of drug targets, stress responses, and the general physiology of the cell.
The paper demonstrates the multifaceted nature of fungal biofilm resistance, which encompasses some of the newest data and
ideas in the field.
1. Clinical Significance of Fungal Biofilms
Fungi represent a significant burden of infection to the
hospital population. The use of broad-spectrum antibiotics,
parenteral nutrition, indwelling catheters, or the presence
of immunosuppression, or disruption of mucosal barriers
due to surgery, chemotherapy, and radiotherapy are among
the most important predisposing factors for invasive fungal
infection [1]. Candida bloodstream infection is the third
most common cause of nosocomial bacteremia in patients
requiring intensive care and the most common etiologic
agent of fungal-related biofilm infection. C. albicans, a
normal commensal of human mucosal surfaces and oppor-
tunistic pathogen in immunocompromised patients, is most
frequently associated with biofilm formation. Indwelling
medical devices, such as intravascular catheters, can become
colonized with Candida spp. allowing the development of
adherent biofilm structures from which cells can then detach
and cause an acute fungemia and/or disseminated infection.
It has recently been shown that the cells that detach from
the biofilm have a greater association with mortality than
equivalent planktonic yeasts [2]. These implant-associated
infections are inherently diﬃcult to resolve and may require
both long-term antifungal therapy and the physical removal
of the implant to control the infection. Other nonalbicans
Candida species associated with biofilm formation and
catheter-related bloodstream or device-related infections
include C. glabrata, C. parapsilosis, C. dubliniensis, C. krusei,
and C. tropicalis [3–5].
Yeasts and filamentous fungi biofilm-related infections
have also been increasingly described [6], including Pneu-
mocystis [7], Coccidioides [8], Aspergillus [9], Zygomycetes
[10], Blastoschizomyces [11], Saccharomyces [12], Malassezia
[13], Trichosporon [14], and Cryptococcus [15]. Cryptococcus
neoformans has been shown to colonize and subsequently
form biofilms on ventricular shunts [15], peritoneal dialysis
fistulas [16], prosthetic hip joints [17], and cardiac valves
[18]. Diﬀerent Trichosporon species can cause disseminated
life-threatening infections associated with biofilm-related
infections [14, 19, 20], including cardiac grafts [21], catheters
[22], and breast implants [23]. Malassezia pachydermatis has
been isolated from patients undergoing parenteral nutrition
[13], Blastoschizomyces capitatus has been associated with
catheter-related fungemia [11], Saccharomyces cerevisiae has
been detected from dentures of stomatitis patients [24], and
recurrent meningitis has been associated with a Coccidioides
immitis biofilm at the tip of a ventriculoperitoneal shunt
tubing [8].
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There are also growing reports of the filamentous mould
Aspergillus fumigatus being involved in biofilm infections.
For example, in the respiratory tract, it can cause an
aspergilloma, which is a localised infection consisting of a
spherical mass of hyphae. Aspergillary bronchitis has also
been reported, which is characterized by bronchial casts
containing mucus and mycelia [25]. Bronchopulmonary
lavage (BAL) of patients with aspergillosis may also reveal
the presence of numerous hyphae in the form of a complex
multicellular mycetoma structure samples when examined
histologically [26]. In addition to this, it has been reported
to cause serious biomaterial-related infections of joint
replacements, catheters, heart valves, cardiac pace makers,
and breast augmentation implants [27–30]. The urinary
tract, whilst less frequently associated with A. fumigatus, has
been reported to support an aspergilloma [31, 32]. It is also
frequently associated with complex sinus infections, which
in canines have been described as superficial mucosal fungal
plaque [33–36].
It is increasingly clear that a diverse panel of fungi have
the capacity to form biofilms, and as such our knowledge
of fungal biofilms has improved dramatically. Through
work primarily with C. albicans, we now have a clearer
perspective on the molecular characteristics of fungal biofilm
development [3, 6, 37, 38]. Clinically, these are important
as they are refractory to antifungal treatment, which poses a
major problem to clinicians as the dose required to eradicate
the biofilm can exceed the highest therapeutically attainable
concentrations of antibiotics [39]. The focus of this paper
is to provide an up-to-date understating of the key factors
responsible for the failure of antifungal agents against fungal
biofilms.
2. Biofilm Basics
Microbiologists have historically studied planktonic (free
floating and homogeneous cells) in pure culture. However,
there has been a paradigm shift as the link between sessile
(surface attached and heterogeneous cells) and microbial
pathogenesis and human infection is now widely accepted
[40]. It is apparent that a wide range of bacteria and fungi are
able to alternate between planktonic growth and sessile mul-
ticellular communities, commonly referred to as biofilms.
Estimates suggest that up to 80% of all microorganisms in
the environment exist in biofilm communities [41].
Biofilms are defined as highly structured communities of
microorganisms that are either surface associated or attached
to one another and are enclosed within a self-produced
protective extracellular matrix (ECM) [6]. The advantages to
an organism of forming a biofilm include protection from
the environment, resistance of physical and chemical stress,
metabolic cooperation, and a community-based regulation
of gene expression. In recent years, there has been an
increased appreciation of the role that fungal biofilms play
in human disease as microbes growing within biofilms
exhibit unique phenotypic characteristics compared to their
planktonic counterpart cells, particularly increased resis-
tance to antimicrobial agents [6]. In addition to providing
safe sanctuary for microorganisms, biofilms may also act as
reservoirs for persistent sources of infection in a patient and
as such adversely eﬀect the health of an increasing number
of individuals, including patients with HIV-infection, cancer,
transplants, patients requiring surgery or intensive care, and
newborn infants [3, 42].
The adhesion and colonization of complex fungal popu-
lations onto biological and innate surfaces, such as the oral
mucosa or denture acrylic substrates, is commonplace for
clinically relevant fungi [43–46]. A wide variety of environ-
mental factors contribute to the initial surface attachment,
including the flow of the surroundingmedium (urine, blood,
saliva, and mucus), pH, temperature, osmolarity, bacteria,
presence of antimicrobial agents, and host immune factors
[47–52]. Fungal biofilms have defined phases of development
that have been described through the use of defined model
systems [51, 53–58]. These key phases include arriving at
an appropriate substratum, adhesion, colonisation, extra-
cellular matrix (ECM) production, biofilm maturation, and
dispersal [37, 55, 59]. Understanding this entire process has
enabled us to begin to unravel how some of the mechanisms
are involved in resistance.
3. Studying Fungal Biofilm Resistance
Initial studies that began to investigate biofilm resistance
were basic, investigating antifungal eﬀects purely at
the phenotypic level through descriptive analyses. The
pioneering work by Julia Douglas’s group working on C.
albicans biofilms utilised some of the earliest models, from
which quantitative assessment using dry weight meas-
urements, tetrazolium salt (MTT) reduction assays, and
incorporation of [3H] leucine were described [60, 61]. These
simple static models were expanded to include flow, which
was shown to alter antifungal susceptibility [47]. However,
typically these models were cumbersome, requiring
expert handling, longer processing times, and the use of
specialized equipment not generally available. Therefore,
methods for rapid high-throughput testing were preferable,
and around this time, the 2,3-bis(2-methoxy-4-nitro-5-
sulfophenyl)-5-[(phenylamino)-carbonyl]-2H-tetrazolium
hydroxide (XTT) colorimetric method was described for
investigating yeast adhesion and susceptibility [62, 63].
This assay measures the collective metabolic activity of the
cells within biofilm and is used as the basis for developing
a standardized high-throughput susceptibility screen on
Candida biofilms, which is now widely used by the research
community [55, 58]. The XTT assay is noninvasive and
nondestructive, requiring minimal postprocessing of sam-
ples compared to other methods, such as viable cell counts
[64]. Using this technique, multiple microtiter plates
can be processed simultaneously without compromising
accuracy. A caveat to its use is that it does not quantify
biofilm-dependant characteristics, such as biomass or
morphological status, and caution must be exercised when
evaluating XTT data from diﬀerent isolates as there is often
dramatic variability between strains [65]. Therefore, it
should only be used for direct comparison of a treated isolate
to an untreated control rather than absolute quantification
of biofilm formation per se. The next breakthrough in
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high-throughput biofilm testing has recently been described
where nanoproduction of C. albicans biofilms is achievable,
creating 768 equivalent and spatially distinct nanobiofilms
on a single glass microarray [66]. However, it remains to be
determined whether there is an assay system sensitive enough
to quantify the metabolic activity of each nanobiofilm.
The recent interest in Aspergillus and Cryptococcus bio-
films, as well as others like Pneumocystis, has led to further
modifications of these, but in essence the platforms and tech-
niques remain largely similar [67]. For example, Martinez
and Casadevall (2006) developed a microtiter plate biofilm
assay for C. neoformans to determine the susceptibility
profiles of in vitro sessile structures [68]. Similarly, a 96-well-
based biofilm model for A. fumigatus has been described and
used to determine the susceptibility profiles and resistance
mechanisms of conidia and adherent hyphal biofilms using
an XTT-based reduction and Alamar blue assays [69–71].
The oxidation reduction indicator Alamar blue has also been
shown to be a reproducible and cheaper alternative to XTT
in recent years, which merits further study [72, 73].
As mentioned, the presence of flowing liquid over the
biofilm can alter antifungal sensitivity [47]. There is a
growing range of flow systems utilized to model biofilm
development [51, 56, 74–76]. For example, a “seed and
feed” modified Robin’s device that permits multiple biofilms
to be formed under constant flow conditions, cylindrical
cellulose filters, constant depth film fermenters, perfusion
fermenters, flow chambers, and a Robbin’s device have
all been described [51, 52, 54, 55, 77, 78]. The Lopez-
Ribot group recently described a simple flow model based
on a gravity-fed flow method that enabled the group to
demonstrate that biofilms were thicker and more resistant
to polyenes and echinocandins by 4- and 2-fold, respectively
[79]. Interestingly, perfusion of biofilms created under flow
with these two antifungal agents showed time- and dose-
dependant activity, which were potent against dispersed cells
[80]. These systems will prove useful for future investigations
of invasive candidiasis where biofilms are common, particu-
larly for catheter-related infections in the ICU, where there
is a growing interest in catheter-lock therapy [81, 82]. In
addition, there are now also a significant number of biofilm
models available for in vivo investigations, and many of these
have been utilised to elucidate biofilm resistancemechanisms
[83], including an implanted chamber under the skin [71],
catheter models [84, 85], vaginal model [86], and denture
model [87].
4. Fungal Biofilm Resistance Mechanisms
One of the defining characteristics of biofilms is their
increased resistance to antimicrobial agents. Fungi have
been reported to be up to 1000-fold more resistant to
antifungal agents than planktonic free-floating cells, yet this
recalcitrance to antimicrobial therapy has yet to be fully
elucidated [14, 58, 88]. Despite some antifungal agents
being eﬃcacious against fungal biofilms, particularly the
echinocandins and liposomal amphotericin B formulations,
the intrinsic resistance exhibited by these complex structures
has promoted detailed investigation [70, 89–92].
Antifungal resistance is both complex and multifaceted.
It can be inducible in response to a compound, or an irre-
versible genetic change resulting from prolonged exposure.
Specifically, these include alterations or overexpression of
target molecules, active extrusion through eﬄux pumps,
limited diﬀusion, tolerance, and cell density, which are
all characterised mechanisms utilised by fungi to combat
the eﬀects of antifungal treatment [93]. Planktonic cells
generally rely on irreversible genetic changes to maintain a
resistant phenotype, whereas biofilms are able to persist due
to their physical presence and the density of the population,
which provides an almost inducible resistant phenotype
irrespective of defined genetic alterations. The following
section will now describe some of the pivotal factors that play
a role in fungal biofilm resistance, which are summarised in
Figures 1 and 2.
4.1. Physiological State. The general physiological state of
cells in sessile populations has also been implicated to
influence the susceptibility profiles of biofilms. Metabolic
dyes assays (e.g., XTT-based assays) confirm that cells within
biofilms are undergoing mitochondrial respiration during
development [55, 58, 62, 65, 70]. Other factors including
the eﬀect of growth rate on C. albicans biofilm resistance
have also been studied, where varying the rates was shown to
play no role in resistance to amphotericin B [54]. Similarly,
biofilms of C. albicans grown under glucose- and iron-
limited conditions were shown to both be highly resistant to
amphotericin B [94]. Furthermore, studies of biofilms grown
under anaerobic conditions demonstrated that C. albicans
biofilms were resistant to the high levels of amphotericin
B and diﬀerent azole antifungals [95]. Nevertheless, factors
including pH, temperature, oxygen availability, and other
environmental stresses will alter the biofilm architecture,
and possibly antifungal sensitivity [96, 97]. Therefore, whilst
the physiological state of the cell may have a minor role
in resistance (e.g., dormancy), it is more likely that more
complex factors are involved.
4.2. Cell Density. The architecture of biofilms is highly
ordered to enable the perfusion of nutrients and expulsion of
waste products. Mature biofilms, whilst densely populated,
exhibit spatial heterogeneity with microcolonies and water
channels being present, and features are common to both
bacterial and fungal biofilms [55, 98, 99]. Cell density is
therefore an important resistance factor within complex
biofilm populations of yeast and filamentous fungal biofilms,
particularly towards azoles. It was demonstrated that both
planktonic and resuspended biofilm cells exhibited azole
sensitivity at low cell numbers (103 cells/ml), which became
increasingly resistant as the density of the cells increased
tenfold [100], a phenomenon also been demonstrated in A.
fumigatus [101]. Both our group and others have shown
phase-dependant increased antifungal resistance in A. fumi-
gatus and C. albicans, respectively [70, 102], which support
the idea that the physical density of the cells within the
biofilm produces recalcitrance to antifungal agents.
Within dense biofilms, there is cooperation between
individual cells through quorum sensing processes, which
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Figure 1: Schematic overview of fungal biofilm resistance mech-
anisms. Generic overview of key biofilm resistance mechanisms
associated with C. albicans, but which are likely to be common
to other fungi. This figure illustrates the density and complexity
of the C. albicans biofilm, with diﬀerent morphotypes present
surrounded by ECM. The arrows represent the diﬀerent factors that
drive antifungal resistance within the biofilm, including density,
stress, persisters, ECM, eﬄux, overexpressed targets, and the general
physiology of the biofilm. These have been placed according to their
contribution to resistance, with those that have a greater eﬀect closer
to the middle and those with less impact at the edges.
provides the ability of microorganisms to communicate
and coordinate their behaviour via the secretion of sig-
nalling molecules in a population-dependent manner [103].
In fungi, this was first described in C. albicans when
Hornby and colleagues identified farnesol trans, trans-3,7,11-
trimethyl-2,6,10-dodecatrien-1-ol [104]. Exposing C. albi-
cans to exogenous farnesol results in genome wide responses,
including activation of genes involved in drug resistance
(CaFCR1 and CaPDR16) [105, 106]. It has now been
shown that quorum sensing in C. albicans is likely driven
by the two-component regulatory system of Chk1p [107].
However, when deleted the Δchk1 strain shows a similar
azole resistance profile to that of wild type [100], indicating
that the regulatory circuit controlling biofilm resistance may
be yet to be discovered, or cell density is not a defined
biofilm resistance factor. However, given that echinocandins
are highly eﬀective against biofilms suggests cell density has
a limited eﬀect against this compound [92]. In addition,
previous work has shown that disrupted biofilms that are
resuspended and tested using the CLSI methodology in
comparison to planktonic cells retain a resistant phenotype
[71, 108], indicating alternative mechanisms of resistance.
4.3. Overexpression of Drug Targets. The azoles are generally
fungistatic against yeasts, including Candida species, and
fungicidal against moulds, such as Aspergillus species. The
fungistatic nature of the azoles towards C. albicans induces
a strong directional selection on the surviving population
to evolve drug resistance [109, 110]. In fact, high levels
of azole resistance in C. albicans clinical isolates often
accumulate through multiple mechanisms including the
alteration of Erg11 [109]. Azoles actively target the 14α-
demethylase enzyme encoded by ERG11, blocking ergosterol
biosynthesis and leads to depletion of the ergosterol content
of membranes and results in the accumulation of toxic sterol
pathway intermediates, such as 14 α-methylergosta-8,24(28)-
dien-3b,6a-diol, which inhibits growth [111, 112]. The
principle drug target, Erg11p, can develop point mutations
or be overexpressed [111–113]. Common mutations in the
Erg11p that confer moderate azole resistance are S405F,
Y132H, R467K, and G464S [114–116].
Given the importance of ergosterol as a target of azoles
and the high level resistance exhibited by these structures,
then the sterol composition of C. albicans biofilms has
been investigated. Sterol analyses showed that ergosterol
levels were significantly decreased in intermediate (12 h)
and mature phases (48 h), compared to those in early-phase
biofilms (6 h) [102]. In contrast, in one of the first C. albicans
biofilm studies to use microarray analysis, overexpression
of CaERG25 and CaERG11 was reported [56]. Alteration
of ergosterols in biofilm membranes may explain their
resistance to both azole and polyene-derived antifungal
agents. For example, C. albicans biofilms cultured in a flow
cell for 36 h were compared to planktonic cells, where it
was shown that a subpopulation of blastospores from the
biofilm were 10 times more resistant to amphotericin B
than planktonic populations [76]. Transcriptional analysis
of this biofilm subpopulation for genes from the beta-1,6-
glucan pathways indicated a possible association between the
high level of resistance and upregulation of CaSKN1, and
CaKRE1 in the biofilm blastospore population compared
to exponential and stationary phase planktonic C. albicans
cells. Therefore, changes in both the cell membrane and
the cell wall may be important determinants of resistance
in the biofilm. Subsequent work in C. albicans has shown
that transcriptional responses in young and mature biofilms
after exposure to high doses of fluconazole or amphotericin
B demonstrated diﬀerential antifungal drug responses [117].
Exposure of both young and mature biofilms to fluconazole
induced upregulation of genes encoding enzymes involved
in ergosterol biosynthesis (CaERG1, CaERG3, CaERG11,
and CaERG25), particularly biofilms exposed for longer
periods (22 h), whereas treatment of both young and mature
biofilms with amphotericin B resulted in an overexpression
of predominantly CaSKN1, with a modest upregulation of
CaKRE1. Removal of the antifungal in this study depleted
further transcriptional changes, except for CaSKN1, which
was impacted by prior fluconazole exposure. It was specu-
lated that this is related to biofilm regrowth. Increased ergos-
terol genes have also been reported in vivo in a C. albicans
central venous catheter biofilm model, demonstrating the
importance of the molecule within the biofilm [118].
Induction of ergosterol genes has also been described
in C. dubliniensis, where incubation with fluconazole and
formation of biofilm was coupled with upregulation of
the CdERG3 and CdERG25 [119]. Moreover, upregulation
of genes involved with ergosterol biosynthesis has been
described in C. parapsilosis biofilms [120], which are also
resistant to azole antifungal therapy [121]. Overall, these data
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Figure 2: Molecular mechanisms of fungal biofilm resistance. Antifungal drug resistance in fungal biofilms is both complex and
multifactorial. The diagram illustrates the mechanisms of diﬀerent class of antifungal agent action (azoles [AZL], polyenes [POL], and
echinocandins [ECN]) and resistance: (a) the layer of ECM present in the biofilm shields the cells from antifungal agents by binding and
reduced penetration; (b) the membrane transporter system ABC and MFS eﬄux pumps extrude antifungal molecules and reduce the
intracellular concentration; (c) mutation in ERG, Cyp51, and FKS1 genes alters the drug target leading to cross-resistance; (d) antifungal
pressure induces stress responses, such as the calcineurin signalling pathway, which is activated, and coping responses occur through
upregulation of various signal transducers. On the right hand side, the table lists diﬀerent resistance genes and their functions, and antifungal
agents aﬀected.
highlight the importance of ergosterol in biofilm resistance,
particularly with respect to azoles, which indirectly inhibit
their biosynthesis. Recent studies have shown that simvas-
tatin, which impairs cholesterol metabolism in humans, is
capable of inhibiting C. albicans biofilms, thus providing
a potential novel strategy of combating these tenacious
infections [122].
4.4. Eﬄux-Pump-Mediated Resistance. The primary molec-
ular mechanism leading to high-level azole resistance in C.
albicans, that is, increased eﬄux of drug mediated mostly
by the ATP-binding cassette (ABC) and the major facili-
tator superfamily (MFS) transporters [123–125]. The ABC
transporters in C. albicans constitute a multigene family,
which includes several CDR genes (CDR1-4) [126, 127]. The
ABC transporters include a membrane pore composed of
transmembrane segments and two ABCs on the cytosolic
side of the membrane, which provide the energy source for
the pump [128, 129]. Importantly, multiple antifungal agents
can be substrates for these transporters, and thus, their
overexpression can lead to cross-resistance among diﬀerent
drugs, particularly azoles. Among members of the MFS,
which are secondary transporters and use proton-motive
force across the plasma membrane, the MDR1 gene encodes
a major facilitator that has been implicated in C. albicans
azole resistance, and its overexpression leads to exclusive
fluconazole resistance [46, 113]. Echinocandin sensitivity is
unaﬀected by eﬄux pumps [130].
Genes encoding for drug eﬄux pumps have been
reported in biofilms to be diﬀerentially regulated during
development and upon exposure to antimicrobial agents
include CaCDR1, CaCDR2, and CaMDR1 [102, 108, 131,
132]. In the first study to investigate the role of eﬄux pumps,
it was demonstrated that expression of genes encoding both
types of eﬄux pump were upregulated during the course
of biofilm formation and development. Both CaCDR1 and
CaCDR2 were upregulated in 24 and 48 h biofilms, whereas
CaMDR1was transiently upregulated at 24 h [108]. However,
their contribution to resistance in the biofilm phenotype
was placed in doubt when a set of C. albicans isogenic
strains deficient in eﬄux pumps carrying single- and double-
deletion mutations (Δcdr1, Δcdr2, Δmdr1, Δcdr1/Δcdr2, and
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Δmdr/Δcdr1) that rendered the cells hypersusceptible to flu-
conazole when planktonic retained the resistant phenotype
during biofilm growth. In a subsequent investigation, C.
albicans biofilms were formed through three distinct devel-
opmental phases that were associated with high fluconazole
resistance. Again, the same set of isogenic C. albicans strains
were utilised where it was shown that 6 h old biofilms formed
by double and triple mutants were >4- to 16-fold more
susceptible to fluconazole than the wild-type strain [102].
At 12 and 48 h, all the strains became highly resistant to
this azole, indicating lack of involvement of eﬄux pumps
in resistance at late stages of biofilm formation. In cell
density studies of the eﬄux pump isogenic strains, these
remain hypersensitive at low cell concentrations yet resistant
at high cell concentrations and in biofilm, indicating a
contributory resistance role of cell density [100]. Never-
theless, similar to the study by Ramage and coworkers
[108], C. albicans biofilms were shown to express CaCDR
and CaMDR1 genes in all three phases (6, 12, and 48 h),
whilst planktonic cells expressed these genes transiently.
In fact, GFP promoter studies have shown induction of
eﬄux pumps after 15min adherence to provide a tolerant
biofilm phenotype [132]. Animal studies have also shown
that biofilms formed on implanted catheters express eﬄux
pumps [84, 118]. Transcript upregulation of CaCDR2 at 12 h
(1.5-fold) and CaMDR1 at both 12 h (2.1-fold) and 24 h (1.9-
fold) was demonstrated [118]. In C. glabrata, similar results
are reported, where expression of CgCDR1 and CgCDR2 was
investigated during the early (6 h), intermediate (15 h), and
mature (48 h) phases of biofilm development. At 6 h and
15 h, the biofilms exhibited approximately 1.5- and 3.3-fold
upregulation of CgCDR1 and 0.5- and 3.1-fold upregulation
of CgCDR2, respectively, in comparison to planktonic cells
[133]. Expression of CtMDR in C. tropicalis biofilms has also
been reported [134].
Collectively, these studies suggest that multifaceted,
phase-specific mechanisms are functional in resistance of
fungal biofilms. This is confirmed in studies of A. fumiga-
tus biofilm resistance. Mutations within the cyp51A gene,
which alters the ergosterol biosynthesis pathway, have been
reported to cause azole resistance in A. fumigatus [135–138].
However, a recent study reported that 43% of azole-resistant
isolates did not carry the cyp51A mutation, indicating that
othermechanisms of resistance were responsible [139]. It was
hypothesised that eﬄux-mediated mechanisms of resistance
may explain this clinical resistance, which may also be
important in biofilms. Sequence analysis suggests that A.
fumigatus has 278 diﬀerent MFS and 49 ABC transporters
[140].A. fumigatusMDR pumps have previously been shown
to be associated with increased resistance to itraconazole
[141, 142]. Currently, however, there is little evidence to
suggest that these play an active role in clinical resistance
[143]. Phase-specific analysis of resistance in A. fumigatus
biofilms revealed increased resistance to azoles, polyenes,
and echinocandins as each biofilm matured from 8 to 12 to
24 h [70, 71]. Biochemical analysis of eﬄux pump activity
showed a significant increase in eﬄux pump activity in the
12 h and 24 h phases, and upregulation in 8 h germlings
when treated with voriconazole. Moreover, inhibition of
eﬄux pump activity with the competitive substrate (MC-
207, 110) reduced the susceptibility to voriconazole by 5-
fold. Quantitative expression analysis of AfuMDR4 mRNA
transcripts revealed a biphasic increase as the mycelial
complexity increased (maximal at 12 h), which was coin-
cidental with strain-dependant increase in azole resistance.
Similar biphasic increases in C. glabrata CDR genes were
also observed [133]. Voriconazole also significantly induced
AfuMDR4 expression, which was also detected in vivo [71].
Global transcriptional analyses of voriconazole-treated A.
fumigatus mycelia of over 2000 genes were shown to be
diﬀerentially expressed, and amongst these was a cluster of 15
diﬀerent transporters mRNA at significantly increased levels,
includingMDR proteins of the ABC andMFS classes, such as
AfMDR1 and AfMDR2 [144]. Also, unpublished microarray
studies of the diﬀerent phases of A. fumigatus biofilms from
our group revealed a cluster of pumps and transporters,
which is similar to studies of C. albicans [131].
Collectively, this data in addition to the available lit-
erature support the hypothesis that eﬄux pumps are an
important, but not exclusive, determinant of fungal biofilm
resistance to azoles [143, 145]. Their primary role may be
for homeostasis within complex environments to protect
themselves from acute toxicity [146], but within clinical
environments exposure to azoles dugs may enhance the levels
of eﬄux pump expression, therefore either contributing
towards or inducing clinical resistance [139]. However, it is
likely that they play a greater protective (resistance) role in
the early phases of biofilm growth until the production of
ECM, one of the primary mechanisms of biofilm resistance.
4.5. Extracellular Matrix. ECM is a defining characteristic of
fungal biofilms, providing the cells protection from hostile
factors such as host immunity and antifungal agents [6].
In some of the pioneering works by the Douglas group,
C. albicans ECM was shown to increase when biofilms
are grown under dynamic flow conditions [47, 48, 53].
However, subsequent work has shown that while diﬀusion
is hampered by ECM, penetration of antifungal drugs is not
thought to play a key role in biofilm resistance [53]. Recent
studies have provided new insights that suggest the chemical
composition of ECM and its regulation may play a central
role in resistance.
The composition of the ECM of these biofilms in C.
albicans and C. tropicalis is complex, comprising of protein,
hexosamine, phosphorus, uronic acid, and carbohydrates
[147]. Recently, it has been shown that extracellular DNA
is another important component of the ECM in C. albicans
[148], as the addition of DNase improves the eﬃcacy of
polyenes and echinocandins, but not to azoles [149]. One of
the principle carbohydrate components is beta-1,3 glucans,
as treatment of C. albicans biofilms with beta-1,3 glucanase
helps detach biofilms from a substrate [147]. Its contribution
is confirmed in a series of investigations by the Andes
group where it was shown to increase in C. albicans biofilm
cell walls compared to planktonic organisms and was also
detected in the surrounding biofilm milieu and as part of
the ECM [150]. Beta-1,3 glucans have also been shown to
increase in investigations of three specific phases of biofilm
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development grown on both denture acrylic and catheter
substrates [151]. Its contribution to resistance was realized
when it was also shown that biofilm cells walls bound 4- to 5-
fold more azole than equivalent planktonic cells, and culture
supernatant bound a quantifiable amount of this antifungal
agent. Moreover, beta-1,3 glucanase markedly improved the
activity of both fluconazole and amphotericin B. Addition
of exogenous biofilm ECM and commercial beta-1,3 glucan
also reduced the activity of fluconazole against planktonic
C. albicans in vitro [150]. The group has recently shown
that the ECM β-1,3 glucan is synthesised from Fks1p using
a defined knockout and overexpressing strain [152]. This
study demonstrated that beta-1,3, glucan is responsible for
sequestering azoles, acting as a “drug sponge” and conferring
resistance on C. albicans biofilms [152]. Further studies
have shown that they are also responsible for sequestering
echinocandins, pyrimidines, and polyenes [153]. This has
been confirmed independently where AMB was shown to
physically bind C. albicans biofilms and beta-glucans [154].
Subsequent studies have identified a role for the CaSMI1,
a gene involved in cell wall glucans, in biofilm ECM
production and development of a drug-resistant phenotype,
which appears to act through transcription factor CaRlmp
and glucan synthase Fks1p [155].
In addition to CaFKS1, a zinc-response transcription
factor CaZAP1 has been shown to be a negative regulator of
ECM soluble beta-1,3 glucan in both in vitro and in vivo C.
albicans biofilmmodels through expression profiling and full
genome chromatin immunoprecipitation [156]. Conversely,
two glucoamylases, CaGCA1 and CaGCA2, are thought to
have positive roles in matrix production. A group of alcohol
dehydrogenases CaADH5, CaCSH1, and CaLFD6 also have
roles in matrix production, with CaADH5 acting positively,
and CaCSH1 and CaLFD6 acting negatively [156]. It is
thought that these alcohol dehydrogenases generate quorum-
sensing aryl and acyl alcohols, which coordinate biofilm
maturation. Collectively, it appears that C. albicans ECM
production is highly regulated and is a key resistance factor. It
is also present on a number of other Candida spp., including
C. glabrata, C. parapsilosis, C. tropicalis, and C. dubliniensis
[157, 158].
Significantly less is known regarding the role of A. fumi-
gatus biofilm ECM in antifungal resistance. In an aerial static
model, the presence of extracellular hydrophobic ECM is
composed of galactomannan, alpha-1,3 glucans, monosac-
charides, polyols, melanin, and proteins, including major
antigens and hydrophobins [159]. This study demonstrated
that hydrophobic matrix cohesively bound hyphae together,
and that the matrix increased with maturity of the devel-
oping structure. Further studies report that a new galac-
tosaminogalactan and the galactomannan were the major
polysaccharides of the in vivo A. fumigatus ECM [160].
Extensive ECM production was also reported as the maturity
of the biofilm increases [9]. For A. niger, after germination
upon a support, the new hyphae also produce an ECM [161].
The production of ECM has also been reported elsewhere,
where it has been shown to be produced on both polystyrene
and cystic fibrosis (CF) bronchial epithelial cells by A.
fumigatus, that were resistant to antifungal agents [162].
Martinez and Casadevall (2006) reported that C. neo-
formans also have the ability to form biofilm structures
in vitro and produce ECM [68]. In Pneumocystis spp.,
confocal microscopy has revealed organisms enmeshed in
ECM. Intense monoclonal antibody staining to the major
surface glycoproteins and an increase in (1,3)-beta-D-glucan
content were also evident, suggesting that these components
contributed to resistance [7]. Blastoschizomyces capitatus,
Malassezia pachydermatis, Saccharomyces cerevisiae, Rhizopus
oryzae, Lichtheimia corymbifera, Rhizomucor pusillus, and
Apophysomyces elegans are all reported to produce ECM in
their biofilms [10, 11, 13, 163]. Therefore, ECM clearly plays
a critical role in fungal biofilm resistance, particularly for C.
albicans, from which we currently understand the greatest.
It is one of the most significant and regulated resistance
mechanisms utilized in the biofilm phenotype.
4.6. Persisters. Persister cells are an important mechanism of
resistance in chronic infections [164], and a mechanism of
resistance that has gathered some attention recently in fungal
biofilms [165–167]. Persister cells are “dormant variants of
regular cells that form stochastically inmicrobial populations
and are highly tolerant to antibiotics” [168]. In C. albicans
biofilms, a small subset of yeast cells have been described that
are highly resistant to amphotericin B following adhesion,
which is independent of upregulation of eﬄux pumps and
cell membrane composition [76, 166]. The first study in
fungi was to describe persister cells in fungi, described as
a subpopulation of highly tolerant cells. In this study, C.
albicans persisters were detected only in biofilms and not
in diﬀerent planktonic populations [166]. Reinoculation of
cells that survived killing of the biofilm by amphotericin
B produced a new biofilm with a new subpopulation
of persisters, suggesting that these were not mutants but
phenotypic variants of the wild type, and that attachment to
a substratum initiated dormancy. The presence of persisters
in C. albicans, C. krusei, and C. parapsilosis biofilms treated
with amphotericin B was also described [169]. It was further
hypothesized that the periodic application of antimicrobial
agents may select for strains with increased levels of persister
cells, so 150 isolates of C. albicans and C. glabrata were
obtained from cancer patients who were at high risk for the
development of oral candidiasis and who had been treated
with topical chlorhexidine once a day. It was shown that
the persister levels of the isolates varied from 0.2 to 9%,
and strains isolated from patients with long-term carriage
had high levels of persisters, whereas those from transient
carriage did not [170]. Therefore, in this clinically relevant
scenario, prolonged and ineﬀectual antifungal treatment
may be beneficial to the biofilm population, which may
be responsible for antimicrobial drug failure and relapsing
infections.
The role of reactive oxygen species (ROS) in sessile
C. albicans cells was investigated as they are known to be
induced by high concentrations of miconazole, allowing 1-
2% of miconazole-tolerant cells to persist [171]. Superoxide
dismutases (Sods) were found to be diﬀerentially expressed
by miconazole-treated sessile C. albicans cells compared to
untreated cells. Inhibition of superoxide dismutase resulted
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in an 18-fold reduction of the miconazole-tolerant persister
cells and increased endogenous ROS levels in these cells
[165]. In biofilms from strains lacking Δsod4/Δsod5, at least
3-fold less miconazole-tolerant persisters were observed, and
ROS levels were increased compared to the isogenic wild
type. Therefore, miconazole-tolerant persisters are linked to
the ROS-detoxifying activity of Sods. Whether this is the
definitive molecular basis for C. albicans persister cells or
a tolerance mechanism still remains to be determined, but
these subpopulations are clearly another important fungal
biofilm resistance mechanism.
4.7. Tolerance. Stress responses have become more fully
realized as defined mechanisms of antifungal resistance.
Pathogenic fungi encounter a range of physiological
stresses from diﬀerent environments, including temperature
changes, ionic stress, changes in osmolarity, and oxidative
stress, such as that experienced in the phagosomes of
neutrophils [112]. These stresses are sensed through various
receptors, which elicit responses through conserved signaling
pathways. One of the most important is the mitogen-
activated protein kinase (MAPK) signal transduction net-
work, and the many others are subject to review [112]. It
was first shown that the mitogen-activated protein kinase
(MAPK) Mck1p, which is activated by contact stress, is
involved in biofilm development. Moreover, the null mutant
(mck1) biofilms were azole sensitive, in contrast to the sessile
wild type and both planktonic strains. This indicates that
Mck1p is involved in biofilm resistance through a stress
pathway [172].
Calcineurin is a Ca2+-calmodulin-activated serine/
threonine-specific protein phosphatase that plays many
critical stress roles in the fungal cell, including amongst other
things antifungal drug responses [173]. In planktonic cells,
calcineurin is critical for C. albicans survival during azole
treatment [174]. Inhibiting calcineurin pharmacologically
or impairing calcineurin function genetically has synergistic
activity with fluconazole and renders the azoles fungicidal
against C. albicans [175]. Calcineurin has also been
implicated in mediating resistance to the azoles in both
in vitro and in vivo models of biofilm formation [176].
C. albicans cells in biofilms are up to 1,000-fold more
resistant to fluconazole than planktonic cells, indicating
that inhibitors could be used in combinations as novel
therapeutic interventions to treat or prevent biofilms,
whereas C. dubliniensis calcineurin inhibitors were unable
to form biofilms [177]. Similar studies have evaluated the
eﬃcacy of a voriconazole-micafungin combination against
C. albicans biofilms. Voriconazole significantly antagonized
the fungicidal eﬀect of micafungin against biofilms. To
investigate the mechanism of antagonism, an inhibitor of
calcineurin was evaluated, which reversed the voriconazole-
induced resistance to micafungin [178]. This study also
suggested that heat shock protein 90 (Hsp90) molecular
chaperone played a role in this antagonism. Hsp90 regulates
complex cellular circuitry in eukaryotes and potentiates
the emergence and maintenance of resistance to azoles and
echinocandins in C. albicans, at least in part via calcineurin
[179]. It physically interacts with the catalytic subunit of
calcineurin, keeping it stable and poised for activation [180].
A recent study led by the Cowen group demonstrated that
genetic depletion of Hsp90 reduced C. albicans biofilm
growth and maturation in vitro and interestingly impaired
dispersal of biofilm cells [181]. It also abrogated resistance
of C. albicans biofilms to the azoles, which was also shown
in vivo. Furthermore, depletion of Hsp90 led to reduction
of calcineurin and Mkc1 in planktonic but not biofilm
conditions, suggesting that Hsp90 regulates drug resistance
through diﬀerent mechanisms. A marked decrease in matrix
glucan levels was observed, providing a mechanism through
which Hsp90 might regulate biofilm azole resistance. In
A. fumigatus, pharmacological depletion of Hsp90 led to
reduced resistance to the echinocandins [181]. Moreover,
a recent investigation of the C. glabrata biofilm proteome
demonstrated upregulation of a heat shock protein (Hsp12p)
and other stress proteins (Trx1p, Pep4p) [182]. Therefore,
targeting Hsp90 may provide a novel strategy for treating
fungal biofilm infections.
5. Conclusions
Fungal biofilm resistance is multifaceted, involving some
basic physical barriers and some complex regulatory pro-
cesses. The evidence that has been collected over the past
decade would suggest that as the biofilm changes from an
adherent phenotype into a complex biofilm, then diﬀerent
mechanisms of resistance are utilised, that is, phase-specific
mechanisms. Clearly, eﬄux pumps are utilised during the
early to intermediate phases of biofilm development but
are relinquished towards maturity as ECM is produced to
“soak” and deplete antifungal agents. The density of the
mature biofilm may act as a physical barrier, and reduction
of growth rates under diﬀerent environmental pressures
can benefit the biofilm. Moreover, during hyphal growth,
ergosterol biosynthesis is regulated by antifungal treatment,
the direct and indirect targets of polyenes and azoles,
respectively. Within the dense biofilms, where penetration of
antifungal drugs is possible, persister cells phenotypes ensure
survival, and in these stressed environments, global stress
proteins kick into action to protect and maintain. Overall,
the evidence highlights that fungal biofilm resistance is an
inducible phenotype that is a part of a highly evolved series of
molecular pathways that regulate biofilm development and
homeostasis.
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